Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Cutaneous adverse events: a predictor of tumor response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients.

Bottlaender L, Amini-Adle M, Maucort-Boulch D, Robinson P, Thomas L, Dalle S.

J Eur Acad Dermatol Venereol. 2020 Feb 20. doi: 10.1111/jdv.16311. [Epub ahead of print]

PMID:
32078191
2.

Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.

Montaudié H, Viotti J, Combemale P, Dutriaux C, Dupin N, Robert C, Mortier L, Kaphan R, Duval-Modeste AB, Dalle S, De Quatrebarbes J, Stefan A, Brunet-Possenti F, Kogay M, Picard-Gauci A, Poissonnet G, Peyrade F.

Oncotarget. 2020 Jan 28;11(4):378-385. doi: 10.18632/oncotarget.27434. eCollection 2020 Jan 28.

3.

Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.

Berger M, Amini-Adlé M, Maucort-Boulch D, Robinson P, Thomas L, Dalle S, Courand PY.

Cancer Med. 2020 Feb 14. doi: 10.1002/cam4.2922. [Epub ahead of print]

4.

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma.

Sonigo G, Battistella M, Beylot-Barry M, Ingen-Housz-Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Socié G, Brice P, Boccara O, Bodemer SC, Adamski H, D'Incan M, Ortonne N, Fraitag S, Brunet-Possenti F, Dalle S, Suarez F, Marcais A, Skowron F, Haidar D, Maubec E, Bohelay G, Laroche L, Mahé A, Birckel E, Bouaziz JD, Brocheriou I, Dubois R, Faiz S, Fadlallah J, Ram-Wolff C, Carlotti A, Bens G, Balme B, Vergier B, Laurent-Roussel S, Deschamps L, Carpentier O, Moguelet P, Herve G, Comoz F, Le Gall F, Leverger G, Finon A, Augereau O, Bléchet C, Kerdraon R, Lamant L, Tournier E, Franck F, Costes-Martineau V, Szablewski V, Taix S, Beschet I, Guerin F, Sepulveda FE, Bagot M, de Saint Basile G, Michonneau D, de Masson A.

Blood. 2020 Jan 31. pii: blood.2019003811. doi: 10.1182/blood.2019003811. [Epub ahead of print] No abstract available.

PMID:
32005988
5.

Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells.

Clement E, Lazar I, Attané C, Carrié L, Dauvillier S, Ducoux-Petit M, Esteve D, Menneteau T, Moutahir M, Le Gonidec S, Dalle S, Valet P, Burlet-Schiltz O, Muller C, Nieto L.

EMBO J. 2020 Feb 3;39(3):e102525. doi: 10.15252/embj.2019102525. Epub 2020 Jan 10.

PMID:
31919869
6.

Radiotherapy-induced or focally enhanced autoimmune blistering diseases.

Pham F, Debarbieux S, Milley S, Balme B, Jouen F, Deberne M, Robinson P, Dalle S.

Eur J Dermatol. 2019 Dec 1;29(6):648-650. doi: 10.1684/ejd.2019.3655. No abstract available.

PMID:
31903957
7.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S.

JAMA Oncol. 2020 Jan 2. doi: 10.1001/jamaoncol.2019.5570. [Epub ahead of print]

8.

microRNA-375 regulates glucose metabolism-related signaling for insulin secretion.

Dumortier O, Fabris G, Pisani DF, Casamento V, Gautier N, Hinault C, Lebrun P, Duranton C, Tauc M, Dalle S, Kerr-Conte J, Pattou F, Prentki M, Van Obberghen E.

J Endocrinol. 2020 Jan 1;244(1):189-200. doi: 10.1530/JOE-19-0180.

PMID:
31697642
9.

Quality-of-life assessment in French patients with metastatic melanoma in real life.

Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I.

Cancer. 2020 Feb 1;126(3):611-618. doi: 10.1002/cncr.32554. Epub 2019 Oct 22.

PMID:
31639198
10.

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.

Corbaux P, Maillet D, Boespflug A, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Dalle S, Falandry C, Péron J.

Eur J Cancer. 2019 Nov;121:192-201. doi: 10.1016/j.ejca.2019.08.027. Epub 2019 Oct 4.

PMID:
31590080
11.

[Creation, implementation and objectives of CARADERM, a national network for rare skin carcinomas - Adnexal neoplasm part].

Seris A, Battistella M, Beylot-Barry M, Dalle S, Mortier L, Lebbé C, Blom A, Neidhart-Berard EM, Kramkimel N, Dupuy A, Zehou O, Dalac S, Jullie ML, Cribier B, Jouary T; Pour CARADERM, réseau de cancers rares dermatologiques (www.caraderm.org); le Groupe de cancérologie cutanée de la Société française de dermatologie.

Ann Dermatol Venereol. 2019 Nov;146(11):704-710. doi: 10.1016/j.annder.2019.07.006. Epub 2019 Sep 30. French.

PMID:
31582261
12.

Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.

Gouillon L, Perier-Muzet M, Amini-Adle M, Poulalhon N, Debarbieux S, Boespflug A, Balme B, Depaepe L, Harou O, Lopez J, Bringuier PP, Ferraro-Peyret C, Maucort-Boulch D, Robinson P, Thomas L, Dalle S.

J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e57-e59. doi: 10.1111/jdv.15906. Epub 2019 Sep 11. No abstract available.

PMID:
31442328
13.

Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.

Jehl A, Cugnet-Anceau C, Vigouroux C, Legeay AL, Dalle S, Harou O, Marchand L, Lascols O, Caussy C, Thivolet C, Laville M, Disse E.

Diabetes Care. 2019 Oct;42(10):2008-2010. doi: 10.2337/dc18-2535. Epub 2019 Aug 21.

PMID:
31434650
14.

Effect of Stacked Sodium Bicarbonate Loading on Repeated All-out Exercise.

Dalle S, De Smet S, Geuns W, Rompaye BV, Hespel P, Koppo K.

Int J Sports Med. 2019 Oct;40(11):711-716. doi: 10.1055/a-0978-5139. Epub 2019 Aug 21.

PMID:
31434137
15.

The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.

Marchand L, Disse E, Dalle S, Reffet S, Vouillarmet J, Fabien N, Thivolet C, Cugnet-Anceau C.

Acta Diabetol. 2019 Dec;56(12):1239-1245. doi: 10.1007/s00592-019-01402-w. Epub 2019 Aug 19. Review.

PMID:
31423559
16.

Concomitant GNA11 and SF3B1 mutations in two cases of melanoma associated with blue naevus.

Danset M, Milley S, Harou O, Vasseur D, Amini-Adle M, Thomas L, Dalle S, Balme B, Lopez J.

Clin Exp Dermatol. 2020 Jan;45(1):123-126. doi: 10.1111/ced.14036. Epub 2019 Jul 23. No abstract available.

PMID:
31338849
17.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC.

Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.

PMID:
31221619
18.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
19.

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C; for MelBase.

JAMA Dermatol. 2019 Jun 1;155(6):673-678. doi: 10.1001/jamadermatol.2019.0425.

PMID:
31042256
20.

A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.

Berger M, Amini-Adlé M, Crumbach L, Paubelle E, Dalle S.

Eur J Cancer. 2019 May;112:94-97. doi: 10.1016/j.ejca.2019.02.006. Epub 2019 Apr 4. No abstract available.

PMID:
30954716
21.

Image Gallery: Unilateral eyebrow depigmentation.

Amini Adle M, Chastagner M, Mansard S, Dalle S.

Br J Dermatol. 2019 Apr;180(4):e107. doi: 10.1111/bjd.17638. No abstract available.

PMID:
30933341
22.

Methods to Study Roles of β-Arrestins in the Regulation of Pancreatic β-Cell Function.

Dalle S, Costes S, Bertrand G, Ravier MA.

Methods Mol Biol. 2019;1957:345-364. doi: 10.1007/978-1-4939-9158-7_22.

PMID:
30919365
23.

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.

Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C.

Eur J Cancer. 2019 May;112:38-46. doi: 10.1016/j.ejca.2019.02.009. Epub 2019 Mar 22.

PMID:
30909072
24.

A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors.

Louveau B, Delyon J, De Moura CR, Battistella M, Jouenne F, Golmard L, Sadoux A, Podgorniak MP, Chami I, Marco O, Caramel J, Dalle S, Feugeas JP, Dumaz N, Lebbe C, Mourah S.

Oncotarget. 2019 Mar 1;10(18):1669-1687. doi: 10.18632/oncotarget.26707. eCollection 2019 Mar 1.

25.

Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.

Péron J, Lambert A, Munier S, Ozenne B, Giai J, Roy P, Dalle S, Machingura A, Maucort-Boulch D, Buyse M.

J Natl Cancer Inst. 2019 Nov 1;111(11):1186-1191. doi: 10.1093/jnci/djz030.

PMID:
30838402
26.

Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database.

Dequidt L, Franck N, Sanchez-Pena P, Dalle S, Adamski H, Boulinguez S, Ingen-Housz-Oro S, Ram-Wolff C, Boccara O, Bonnet N, Cortes B, Gouraud A, Grange F, Le Corre Y, Quereux G, De Masson A, Schmutz JL, Skowron F, Verneuil L, Beylot-Barry M.

Br J Dermatol. 2019 Sep;181(3):616-618. doi: 10.1111/bjd.17834. Epub 2019 May 29. No abstract available.

PMID:
30835817
27.

The role of omega-3 in the prevention and treatment of sarcopenia.

Dupont J, Dedeyne L, Dalle S, Koppo K, Gielen E.

Aging Clin Exp Res. 2019 Jun;31(6):825-836. doi: 10.1007/s40520-019-01146-1. Epub 2019 Feb 19. Review.

28.

A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.

Berger M, Amini-Adlé M, Crumbach L, Paubelle E, Dalle S.

Eur J Cancer. 2019 Mar;110:49-52. doi: 10.1016/j.ejca.2019.01.011. Epub 2019 Feb 8. No abstract available.

PMID:
30739840
29.

[Precision medicine in oncology: Challenges, stakes and new paradigms].

Cox S, Rousseau-Tsangaris M, Abou-Zeid N, Dalle S, Leurent P, Cutivet A, Le HH, Kotb S, Bogaert B, Gardette R, Baran Y, Holder JM, Lerner L, Blay JY, Cambrosio A, Tredan O, Denèfle P.

Bull Cancer. 2019 Feb;106(2):97-104. doi: 10.1016/j.bulcan.2019.01.007. Epub 2019 Feb 1. French. No abstract available.

PMID:
30713005
30.

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.

Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, Péron J.

Int J Cancer. 2019 Aug 1;145(3):639-648. doi: 10.1002/ijc.32132. Epub 2019 Feb 4.

PMID:
30653255
31.

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

Marchand L, Reffet S, Dalle S, Disse E, Vouillarmet J, Cugnet-Anceau C, Thivolet C.

Acta Diabetol. 2019 Mar;56(3):377-378. doi: 10.1007/s00592-018-1262-4. Epub 2018 Dec 1. No abstract available.

PMID:
30506459
32.

[Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].

Amini-Adle M, Balme B, Dalle S.

Ann Dermatol Venereol. 2018 Dec;145(12):802-803. doi: 10.1016/j.annder.2018.10.016. Epub 2018 Nov 9. French. No abstract available.

PMID:
30415933
33.

Reply to "Comment on 'Association of subungual melanoma and subungual squamous cell carcinoma: A case series'".

Boespflug A, Debarbieux S, Depaepe L, Chouvet B, Maucort-Boulch D, Dalle S, Balme B, Thomas L.

J Am Acad Dermatol. 2019 Mar;80(3):e63-e64. doi: 10.1016/j.jaad.2018.10.047. Epub 2018 Oct 27. No abstract available.

PMID:
30393092
34.

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.

Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I.

Eur J Cancer. 2018 Dec;105:33-40. doi: 10.1016/j.ejca.2018.09.026. Epub 2018 Oct 29.

PMID:
30384014
35.

Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.

Berger M, Legeay AL, Souci S, Streichenberger N, Thomas L, Dalle S.

Eur J Cancer. 2018 Nov;104:227-230. doi: 10.1016/j.ejca.2018.08.021. Epub 2018 Oct 12. Review. No abstract available.

PMID:
30322679
36.

Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.

Marchand L, Thivolet A, Dalle S, Chikh K, Reffet S, Vouillarmet J, Fabien N, Cugnet-Anceau C, Thivolet C.

Acta Diabetol. 2019 Apr;56(4):441-448. doi: 10.1007/s00592-018-1234-8. Epub 2018 Oct 4.

PMID:
30284618
37.

Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.

Leclerc J, Garandeau D, Pandiani C, Gaudel C, Bille K, Nottet N, Garcia V, Colosetti P, Pagnotta S, Bahadoran P, Tondeur G, Mograbi B, Dalle S, Caramel J, Levade T, Ballotti R, Andrieu-Abadie N, Bertolotto C.

Oncogene. 2019 Feb;38(8):1282-1295. doi: 10.1038/s41388-018-0500-0. Epub 2018 Sep 25.

PMID:
30254208
38.

[Oral and mucosal lichenoid drug eruption under anti-PD-1].

Amini-Adle M, Balme B, Locatelli-Sanchez M, Souquet PJ, Dalle S.

Ann Dermatol Venereol. 2018 Nov;145(11):725-727. doi: 10.1016/j.annder.2018.07.004. Epub 2018 Aug 17. French. No abstract available.

PMID:
30126642
39.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators.

Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

40.

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.

Amini-Adle M, Khanafer N, Le-Bouar M, Duru G, Dalle S, Thomas L.

BMC Cancer. 2018 Jul 3;18(1):705. doi: 10.1186/s12885-018-4618-9.

41.

Evaluation of large clinically atypical vulvar pigmentation with RCM: atypical melanosis or early melanoma?

Theillac C, Cinotti E, Malvehy J, Ronger Savle S, Balme B, Robinson P, Perrot JL, Douchet C, Biron Schneider AC, Alos L, Garcia A, Barreiro A, Labeille B, Duru G, Dalle S, Thomas L, Debarbieux S.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):84-92. doi: 10.1111/jdv.15141. Epub 2018 Jul 12.

PMID:
29920797
42.

[Vitiligo under checkpoint inhibitors].

Amini-Adle M, Dalle S.

Ann Dermatol Venereol. 2018 Oct;145(10):633-635. doi: 10.1016/j.annder.2018.04.006. Epub 2018 Jun 14. French. No abstract available.

PMID:
29866472
43.

The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.

Vial J, Royet A, Cassier P, Tortereau A, Dinvaut S, Maillet D, Gratadou-Hupon L, Creveaux M, Sadier A, Tondeur G, Léon S, Depaepe L, Pantalacci S, de la Fouchardière A, Micheau O, Dalle S, Laudet V, Mehlen P, Castets M.

Cell Death Differ. 2019 Mar;26(3):443-454. doi: 10.1038/s41418-018-0128-1. Epub 2018 May 31.

PMID:
29855541
44.

Proteasomal degradation of the histone acetyl transferase p300 contributes to beta-cell injury in a diabetes environment.

Ruiz L, Gurlo T, Ravier MA, Wojtusciszyn A, Mathieu J, Brown MR, Broca C, Bertrand G, Butler PC, Matveyenko AV, Dalle S, Costes S.

Cell Death Dis. 2018 May 22;9(6):600. doi: 10.1038/s41419-018-0603-0.

45.

A noninterfering system to measure in-cage spontaneous physical activity in mice.

Poffé C, Dalle S, Kainz H, Berardi E, Hespel P.

J Appl Physiol (1985). 2018 Aug 1;125(2):263-270. doi: 10.1152/japplphysiol.00058.2018. Epub 2018 Apr 26.

46.

[Digital mucous cyst].

Deschamps T, Perier-Muzet M, Thomas L, Dalle S.

Ann Dermatol Venereol. 2018 May;145(5):385-386. doi: 10.1016/j.annder.2018.03.005. Epub 2018 Apr 17. French. No abstract available.

PMID:
29678395
47.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

48.

[Alopecia areata under ipilimumab].

Amini-Adle M, Dalle S.

Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):465-466. doi: 10.1016/j.annder.2018.03.003. Epub 2018 Apr 10. French. No abstract available.

PMID:
29653853
49.

A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.

Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP.

J Invest Dermatol. 2018 Sep;138(9):1982-1989. doi: 10.1016/j.jid.2018.03.1516. Epub 2018 Mar 27.

50.

Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.

Menguy S, Frison E, Prochazkova-Carlotti M, Dalle S, Dereure O, Boulinguez S, Dalac S, Machet L, Ram-Wolff C, Verneuil L, Gros A, Vergier B, Beylot-Barry M, Merlio JP, Pham-Ledard A.

Mod Pathol. 2018 Aug;31(8):1332-1342. doi: 10.1038/s41379-018-0041-7. Epub 2018 Mar 26.

Supplemental Content

Support Center